Saxendapro.com Website Review

as an adjunct to a reduced-calorie diet and increased physical activity. click for limitations of use. warning: risk of thyroid c-cell tumors liraglutide causes dose-dependent and treatment-duration-dependent thyroid c-cell tumors at clinically relevant exposures in both genders of rats and mice. it is unknown whether saxenda® causes thyroid c-cell tumors, including medullary thyroid carcinoma (mtc), in humans, as the human relevance of liraglutide-induced rodent thyroid c-cell tumors has not been determined. saxenda® is contraindicated in patients with a personal or family history of mtc and in patients with multiple endocrine neoplasia syndrome type 2 (men 2). counsel patients regarding the potential risk of mtc with use of saxenda® and inform them of symptoms of thyroid tumors (eg, a mas* in the neck, dysphagia, dyspnea, persistent hoarseness). routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of mtc in patients treated with saxenda®. (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, type 2 diabetes mellitus, or liraglutide, and therefore should not be used together. saxenda® should not be used in combination with any other glp-1 receptor over-the-counter drugs, and herbal preparations, have not been established patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated  in patients treated with liraglutide postmarketing. observe patients carefully for signs and symptoms of pancreatitis (persistent severe abdominal pain, sometimes radiating to the back with or without vomiting). if pancreatitis is suspected, discontinue saxenda® increase the risk of cholelithiasis; however, the incidence of acute gallbladder disease was greater in patients treated with saxenda® than with placebo even after accounting for the degree of weight loss. if cholelithiasis is suspected, gallbladder studies and appropriate